They're laying the groundwork for legislation and regulation to counter Chinese biopharma companies. Eli Lilly Donald Trump Obesity Newsletters Log In My Account Subscribe Now My Account Settings Complete your personal information for a more tailored experience Billing Log Out A decade of reporting from the frontiers of health and medicine Newsletters Log In My Account Subscribe Now Biotech Pharma Public Health Health Tech Policy Science First Opinion STAT+ STAT Events Search Log In Try STAT+ My Account Home Politics Biosecure didn’t stop China’s rise in biotech. Some lawmakers want to do more New laws, more regulation of Chinese biopharma…
WASHINGTON — Last year, Congress passed a bill restricting how U.S. pharmaceutical and biotechnology companies can do business with Chinese firms. Many political leaders don’t seem to be satisfied.
Already, they’re laying the groundwork for additional legislative and regulatory measures to counter the rise of Chinese biopharma companies. And federal health officials are working to make it easier for companies to operate in the U.S.
“The itch has not been entirely scratched,” said Bobby McMillin, partner at Arnold Porter.
Continue to STAT+ to read the full story…
US Pharma Marketing